Neuromyelitis Optica (NMO) is a rare demyelinating disease, recently segregated from other demyelinating diseases due to its distinctive features that set it apart from multiple sclerosis (MS) and other central nervous system (CNS) disorders. Particularly, the presence of autoantibodies against myelin oligodendrocyte glycoprotein (MOG) has emerged as a specific subtype of NMO, known as MOGAD. This article presents a unique case in which a physician, with a specialization in neuroimmunology, personally experiences the challenges of delayed diagnosis and clinical management of this disease.
No takes yet. Share an insight, caveat, or question.
Estrella Rodríguez (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: